AstraZeneca has sailed away from a licensing deal for Pieris Pharmaceuticals’ asthma med, forcing the biotech to begin charting a new corporate course and lay off 70% of its staff in the process. The ...

AstraZeneca has terminated a partnership with Pieris Pharmaceuticals on respiratory drug candidate elarekibep, forcing the latter to slash staff and look into its “strategic options”. AZ bought into ...

Under the collaboration agreement, AstraZeneca will make an upfront payment of $57.5 million and near-term milestone payments of $12.5 million to Pieris once it initiated Phase 1 trial for PRS-060.

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Pieris Pharmaceuticals ( (PIRS)) has ...

My first spring catalog has come. The excitement at our house is at a winter high — thinking of all of the green that comes with spring and the opportunities to add to my landscape. I have marked ...

FREISING-WEIHENSTEPHAN, Germany, January 4 /PRNewswire/ -- Pieris AG today announced the appointment of Stephen S. Yoder as CEO with immediate effect. Mr. Yoder takes over the position from interim ...

Pieris Pharmaceuticals’ long-standing immuno-oncology alliance with Servier is being dissolved after a clinical trial of the lead drug in the alliance revealed a safety concern. In a Securities & ...

The signing of a lucrative collaboration deal causes the share price to jump. This deal provides Pieris with an up-front payment of $30 million and the ability to earn up to $1.2 billion in milestone ...

BOSTON, MA / ACCESSWIRE / March 29, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® ...

Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there ...